Posted by Michael Wonder on 08 Feb 2023
Santhera concludes agreement with French authorities on Raxone reimbursement and plans to submit a request for an early access program for vamorolone
8 February 2023 - Santhera Pharmaceuticals announces that it has secured a final reimbursement agreement with the French authorities related to Raxone (idebenone) for the treatment of Leber's hereditary optic neuropathy and sales are expected to resume shortly.
In addition, the Company plans to submit a request in France in the near-term for an early access program for vamorolone for the treatment of Duchenne muscular dystrophy.
Since its introduction in 2015, Raxone was available to patients in France for the treatment of LHON and reimbursed under a temporary financing scheme (formerly known as ATU).
